Abbott used this approach to compare various combinations PI dosing regimens which included low and moderate dose ritonavir and were able to predict:
The range of peak and trough concentrations for each of the PI’s in the regimen, and the ratio of trough concentrations to IC50 values
The effect of varying degrees of nonadherence on the fraction of patients who were likely to experience virological failure
The PK/PD model and the simulations done with it were observed to be consistent with data from several actual trials carried out by Abbott